(Q60920290)

English

Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan

scientific article published on 05 January 2019

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Behçet's disease

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

author name string

Itsuro Umebayashi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Miyuki Matsukawa

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Takashi Goto

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Toshiro Yano

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

language of work or name

0 references

publication date

5 January 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Arthritis Research and Therapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

copyright license

Creative Commons Attribution 4.0 International

5 January 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s13075-018-1793-7

0 references

Enhanced production of in vitro tumor necrosis factor-alpha from monocytes in Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of genital ulcers with infliximab in Behcet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of long-term cyclosporine A therapy on renal functions in Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential target of infliximab in autoimmune and inflammatory diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease]

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Guidelines for the clinical management of ocular Behçet's disease ]

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Major Review: Current Aspects of Ocular Behçet's Disease in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis-A Cohort Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30611312

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13075-018-1793-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30611312%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60920290&oldid=2116762711"